| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 15/04/2024 | 14h00 | Business Wire | Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd. | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 11/03/2024 | 11h19 | Edgar (US Regulatory) | Form SC 13E3/A - Going private transaction by certain issuers: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 15/02/2024 | 14h36 | Edgar (US Regulatory) | Form SC 13E3 - Going private transaction by certain issuers | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 30/01/2024 | 19h18 | PR Newswire (US) | Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law Firm | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 30/01/2024 | 13h00 | PR Newswire (US) | Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 26/01/2024 | 15h00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 25/01/2024 | 23h06 | Business Wire | Taro Provides Results for December 31, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 19/01/2024 | 22h15 | Business Wire | Taro to Release Third Quarter Results on January 25, 2024 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 17/01/2024 | 22h36 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 17/01/2024 | 22h35 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 17/01/2024 | 22h30 | PR Newswire (Canada) | Taro Announces Merger Agreement with Sun Pharma | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 17/01/2024 | 22h30 | PR Newswire (US) | Taro Announces Merger Agreement with Sun Pharma | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 04/01/2024 | 22h30 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 11/12/2023 | 22h31 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 11/12/2023 | 22h30 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 17/11/2023 | 22h30 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 27/10/2023 | 15h00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 26/10/2023 | 23h00 | Business Wire | Taro Provides Results for September 30, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 19/10/2023 | 22h30 | Business Wire | Taro to Release Second Quarter Results on October 26, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 27/07/2023 | 16h00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 27/07/2023 | 02h36 | Business Wire | Taro Provides Results for the Quarter Ended June 30, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 19/07/2023 | 22h00 | Business Wire | Taro to Release First Quarter Results on July 26, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 19/07/2023 | 13h00 | PR Newswire (US) | Krensavage Asset Management Opposes Sun's Lowball Bid for Taro | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 30/06/2023 | 15h00 | Business Wire | Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023 | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 29/06/2023 | 22h32 | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 28/06/2023 | 23h01 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 28/06/2023 | 23h00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 31/05/2023 | 23h01 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 26/05/2023 | 23h03 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NYSE:TARO | Taro Pharmaceutical Industries Ltd |
| 26/05/2023 | 23h02 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NYSE:TARO | Taro Pharmaceutical Industries Ltd |